CAJ | 학술논문

为了比较胞浆CD79a(CyCD79a)与包括胞浆CD22(CyCD22)、CD19、CD20和CD10等其它4种常用B系相关抗原在各种急性白血病细胞上的表达情况并寻找针对急性前体B淋巴细胞白血病(pB-ALL)的最敏感和特异的免疫学标志,对采用流式细胞术方法检测的221例成人和儿童急性白血病的免疫表型资料及常规细胞形态学和酶细胞化学染色资料进行了回顾性分析.另外,还对其中的45例急性早幼粒细胞白血病和13例怀疑存在AML1/ETO和CBFβ/MYH11等融合基因的急性髓细胞白血病(AML)进行了细胞遗传学和/或分子生物学检测.结果发现,对于pB-ALL来说,在这5种常用的B系抗原中,CyCD79a的敏感性最高,而CyCD22的特异性最好.CyCD79a在全部58例pB-ALL中的表达率为100%,而CyCD22在全部147例AML和15例急性前体T淋巴细胞白血病(pT-ALL)中则无1例表达,即在非pB-ALL的急性白血病中的表达率为0%.结论:联合检测CyCD79a和CyCD22是诊断pB-ALL的最合适的免疫学指标,能够准确地将pB-ALL与AML,和pT-ALL相鉴别.
위료비교포장CD79a(CyCD79a)여포괄포장CD22(CyCD22)、CD19、CD20화CD10등기타4충상용B계상관항원재각충급성백혈병세포상적표체정황병심조침대급성전체B림파세포백혈병(pB-ALL)적최민감화특이적면역학표지,대채용류식세포술방법검측적221례성인화인동급성백혈병적면역표형자료급상규세포형태학화매세포화학염색자료진행료회고성분석.령외,환대기중적45례급성조유립세포백혈병화13례부의존재AML1/ETO화CBFβ/MYH11등융합기인적급성수세포백혈병(AML)진행료세포유전학화/혹분자생물학검측.결과발현,대우pB-ALL래설,재저5충상용적B계항원중,CyCD79a적민감성최고,이CyCD22적특이성최호.CyCD79a재전부58례pB-ALL중적표체솔위100%,이CyCD22재전부147례AML화15례급성전체T림파세포백혈병(pT-ALL)중칙무1례표체,즉재비pB-ALL적급성백혈병중적표체솔위0%.결론:연합검측CyCD79a화CyCD22시진단pB-ALL적최합괄적면역학지표,능구준학지장pB-ALL여AML,화pT-ALL상감별.
To evaluate the expression of cytoplasmic CD79a (CyCD79a) and other commonly used B-lymphoid immunomarkers including cytoplasmic CD22 (CyCD22), CD19, CD20 and CD10 in various acute leukemia cells and to define the most sensitive and specific markers in the diagnosis of precursor B-cell acute lymphoblastic leukemia ( pB-ALL), the immunophenotypic data from 221 de novo adult and pediatric acute leukemia patients as studied using multiparameter flow cytometry in addition to routine morphologic and enzyme cytochemical assay, were retrospectively analyzed. Cytogenetic and/or molecular biological data in all 45 cases of acute promyelocytic leukemia (APL) and 13 cases of acute leukemia suspected as AML with the fusion genes such as AML1/ETO and CBFβ/MYH11 were investigated.The results showed that CyCD79a and CyCD22 were the most sensitive and specific markers respectively for pB-ALL.Expression of CyCD79a was seen in 100% of 58 cases of pB-ALL. At the same time, none (0%) of all 147 cases of acute myeloid leukemia (AML) and 15 cases of precursor T-cell acute leukemia (pT-ALL) was positive for CyCD22.The conclusion is made that united detection of CyCD79a and CyCD22 is the optimal immune combination for the diagnosis pB-ALL and the distinguishing pB-ALL with AML and pT-ALL.